HAZLET, N.J. - TelAve -- In this symposium, ATTR experts will describe strategies for improving recognition of clinical clues for ATTR-CM and for making an earlier and accurate diagnosis. Evidence with disease-modifying therapies for ATTRCM will be presented including interpretations of recently completed clinical trials. Most effective use of HF medications in ATTR-CM patients will also be discussed. Two cases with panel discussions will be presented, 1) avoiding pitfalls and explaining best practices to overcome management challenges, and 2) successfully addressing the complexities of diagnosing hereditary ATTR-CM and recognizing the importance of genetic testing not only for the index patient but also for identifying at-risk family members and initiating evidence-based interventions.

Click here for more information

More on TelAve News

• Postmortem Pathology Highlights Private Autopsy Options for Las Vegas Families During Summer Months
• Postmortem Pathology Offers Sacramento Families Independent Answers on a Short Timeline
• NEW Three Fully Furnished Single-Family Model Homes at Heritage at South Brunswick
• After 35 Years, Christian Radio Host Marina Maria Publishes the Novel She Never Forgot
• Freight Broker 911 CEO and President Milton Collier Is Rebuilding the Path Into Freight Brokerage

CHAIR

Mathew Maurer, MD
Arnold and Arlene Goldstein Professor of Cardiology
Professor of Medicine
Columbia University Irving Medical Center
Vagelos College of Physicians & Surgeons
New York, New York

FACULTY

Sarah Cuddy, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Justin Grodin, MD, MPH
Associate Professor of Medicine
Department of Internal Medicine – Division of Cardiology
University of Texas Southwestern Medical Center
Dallas, Texas

Ahmad Masri, MD, MS
Associate Professor of Medicine
Oregon Health & Science University
Portland, Oregon

Educational Objectives

• Identify suggestive findings for ATTR-CM
• Summarize the diagnostic evaluation for cardiac amyloidosis
• Interpret the evidence for ATTR-CM disease-modifying therapies
• Discuss strategies for the use of HF medications in patients diagnosed with ATTR-CM
• Explain the importance of genetic testing in the diagnosis of ATTR-CM
• Describe the challenges associated with the management of transthyretin amyloidosis

Target Audience

More on TelAve News

• Boston Industrial Solutions Launches New and Improved Siliart Website for Silicone Decorators
• Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Phoenix
• Sky Quarry's Big Turning Point: CEO Marcus Laun Outlines the Next Phase for N A S D A Q: SKYQ
• Hunter Is Releasing New Music For The Holidays!
• Tixpool.com - Naija Premier Event Reseller

This educational activity is intended for cardiovascular clinicians.

Educational Grant

Voxmedia gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals LP and Ionis Pharmaceuticals.

Accreditation and Credit Designation Statements

Voxmedia, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Voxmedia, LLC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity. Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.
The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.